Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 13, Number 7—July 2007

Research

Antimicrobial Drugs and Community-acquired Methicillin-Resistant Staphylococcus aureus, United Kingdom

Verena Schneider-Lindner*†, J. A. Delaney*†, Sandra Dial†‡, Andre Dascal‡, and Samy Suissa*†Comments to Author 
Author affiliations: *McGill University Health Center, Montreal, Quebec, Canada; †Royal Victoria Hospital, Montreal, Quebec, Canada; ‡Sir Mortimer B. Davis–Jewish General Hospital, Montreal, Quebec, Canada;

Main Article

Table 3

Risk for infection with community-acquired methicillin-resistant Staphylococcus aureus (MRSA)*

Class of antimicrobial drug Case-patients
(N = 1,981), no. (%) Control-patients
(N = 19,779), no. (%) Crude OR Adjusted OR† 95% CI
No prescription (reference group) 770 (38.9) 12,821 (64.8) 1 1
Cephalosporins 27 13.6 () 994 (5.0) 2.01 1.85 1.57–2.19
Macrolides 32 (16.2) 1,04 (5.2) 2.70 2.50 2.14–2.91
Penicillins 540 (27.3) 3,104 (15.7) 1.67 1.56 1.39–1.76
Other antimicrobial drugs 204 (10.3) 1,615 (8.1) 2.02 1.90 1.61–2.24
Sulfonamides 260 (13.1) 1,114 (5.8) 1.77 1.74 1.48–2.04
Tetracyclines 77 (3.9) 461 (2.3) 1.14 1.09 0.83–1.43
Quinolones 218 (11.0) 434 (2.2) 3.81 3.37 2.80–4.09

*For persons prescribed different classes of antimicrobial drugs in the 30–365 days before their index date, relative to risk for MRSA infection in persons with no prescriptions during the same period. Data from General Practice Research Database, United Kingdom, 2000–2004. OR, odds ratio; CI, confidence interval.
†Adjusted for prescriptions from other antimicrobial drug classes in the 30–365 days before the index date and all variables in Table 1.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO